Federal Judge Blocks RFK Jr. Vaccine Policy Shift: Spikevax's Path Forward Stabilized

A U.S. court ruling halts controversial changes to childhood vaccine recommendations, preserving market stability for Moderna's Spikevax amid ongoing policy battles and strong 2025 performance.

A federal judge in Boston ruled on March 16, 2026, blocking Health Secretary Robert F. Kennedy Jr.'s key changes to U.S. vaccine policy, including downgrades to COVID-19 shot recommendations that directly impact Moderna's Spikevax. This decision safeguards Spikevax's position in the U.S. market, where it captured 24% of retail COVID vaccinations in 2025, especially critical as DACH investors eye U.S. policy volatility affecting biotech revenues.

As of: 17.03.2026

Dr. Elena Voss, Biotech Policy Analyst: Spikevax stands at the intersection of mRNA innovation and U.S. regulatory turbulence, shaping Europe's vaccine access strategies.

Breakdown of the Court Ruling on Vaccine Policy

U.S. District Judge Brian Murphy invalidated votes by the Advisory Committee on Immunization Practices (ACIP) to reduce routine childhood vaccinations and downgrade recommendations for six diseases, including COVID-19 shots.

The ruling specifically blocked RFK Jr.'s 13 appointees to ACIP, deeming the committee unlawfully constituted under the Federal Advisory Committee Act.

This action postpones an ACIP meeting and restores prior recommendations for hepatitis B newborn vaccines and broader COVID-19 immunizations.

Plaintiffs, led by the American Academy of Pediatrics, argued the changes threatened public health by eroding vaccination rates.

The decision marks a setback for Kennedy's agenda to address perceived declines in vaccine trust post-COVID-19.

Spikevax's Dominant 2025 Market Performance

Spikevax emerged as a cornerstone U.S. product in 2025, accounting for roughly 24% of all retail COVID vaccinations and nearly one-third among adults aged 65 and older.

This performance underscores Spikevax's entrenched role in the ongoing COVID-19 immunization landscape despite evolving variants and policy shifts.

Moderna's broader infectious disease portfolio advanced with three U.S. regulatory approvals, strong Phase 3 flu vaccine efficacy data, and progress in flu + COVID combination and Norovirus programs.

These developments position Spikevax within a diversifying franchise potentially expanding to six approved products.

Commercial Implications for Spikevax Demand

The court's intervention prevents immediate erosion of Spikevax recommendations, maintaining its eligibility under public health programs and insurance coverage.

Vaccine makers, including Moderna, have expressed wariness over U.S. policy under Kennedy, with pediatricians reporting rising parental skepticism.

Nearly a dozen states consider relaxing school vaccine mandates, amplifying risks to routine immunization volumes.

Yet Spikevax's adult-focused strength, particularly in seniors, buffers against childhood schedule changes.

Preserved ACIP status ensures Spikevax remains a frontline option for seasonal COVID boosters, critical for recurrent revenue.

Moderna's Financial Resilience Backing Spikevax

Moderna reported $1.9 billion in total revenue for 2025, alongside $2.2 billion in annual cost savings, a 30% reduction from 2024 levels.

The company holds $8.1 billion in cash, cash equivalents, and investments as of December 31, 2025, bolstered by a $1.5 billion five-year term loan facility.

These resources fund pipeline execution, including pivotal 2026 trial readouts in oncology, rare diseases, and infectious diseases.

Spikevax's cash generation supports investments in oncology collaborations with Merck, now featuring eight Phase 2/3 trials.

Investor Context: Moderna Stock (US60770K1079)

Moderna shares rose 1.4% on March 16 following the ruling, reflecting relief over policy stability.

DACH investors track this via U.S.-listed shares, with Spikevax performance directly influencing revenue amid Europe's parallel vaccine dynamics.

Longer-term, pipeline diversification reduces reliance on COVID products like Spikevax.

Pipeline Momentum Beyond Spikevax

Moderna anticipates launching flu, flu + COVID combination, and Norovirus vaccines, expanding the infectious disease franchise.

Norovirus enrollment completed its second Northern Hemisphere cohort in January 2026.

Oncology efforts include early-stage portfolio growth alongside Merck partnerships.

Rare disease programs advance, with Board oversight ensuring disciplined capital allocation.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.